Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05763875 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.
A Phase 3 study of Hypercholesterolemia, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 350
- Enrollment target
- 20
- Study locations
NCT05763875 is a Phase 3 study of Hypercholesterolemia that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 350 participants, below the 811-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (57% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT05763875, a Phase 3 study of Hypercholesterolemia, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 350 participants
- Enrollment target
- 20
- Study locations
Study Summary
CKJX839D12304 was a research study to determine if the study treatment, called inclisiran, in comparison to placebo and ezetimibe effectively reduces Low-Density Lipoprotein Cholesterol (LDL-C) as measured by percentage change from baseline to Day 150. This study was conducted in eligible participants with primary hypercholesterolemia not receiving any lipid-lowering therapy (LLT), with a 10-year Atherosclerotic Cardiovascular Disease (ASCVD) risk of less than 7.5%.
Conditions Studied
Interventions
- DRUG Ezetimibe
- DRUG Inclisiran
- DRUG Matching Placebo for Inclisiran
- DRUG Matching Placebo for Ezetimibe
Study Locations (20)
Florida
- Hillcrest Medical Research - DeLand
- ClinCloud - Maitland
- Alma Clinical Research Inc - Miami
- Inpatient Research Clinical LLC - Miami Lakes
- Harmony Clinical Research - North Miami Beach
- Fam Medical Specialists Of Fl Plc - Plant City
- Cozy Research LLC - Zephyrhills
Louisiana
- Grace Research LLC - Bossier City
- Grace Research Llc - Shreveport
- Southern Clin Research Clinic - Zachary
Alabama
- Parkway Medical Center - Birmingham
- SEC Clinical Research - Dothan
Illinois
- Koch Family Medicine - Morton
New York
- Prime Global Research Inc - The Bronx
North Carolina
- Monroe Biomedical Research - Monroe
North Dakota
- Lillestol Research LLC - Fargo
Ohio
- WellNow Urgent Care and Research - Huber Heights
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2023-03-15 |
| Est. Completion | 2024-06-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05763875
The ClinicalTrials.gov registry entry for NCT05763875 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 811-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (57% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypercholesterolemia appearing as the primary indexed condition, and to 4 interventions - of which Ezetimibe is the first listed.
NCT05763875 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, Louisiana, Alabama.
Frequently Asked Questions
What is clinical trial NCT05763875 about?
NCT05763875 is a clinical study titled "Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.". CKJX839D12304 was a research study to determine if the study treatment, called inclisiran, in comparison to placebo and ezetimibe effectively reduces Low-Density Lipoprotein Cholesterol (LDL-C) as measured by percentage change from baseline to Day 150. This study was conducted in eligible participan...
What is the current status of trial NCT05763875?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 350 participants. The study started on 2023-03-15. Estimated completion is 2024-06-20.
What conditions does trial NCT05763875 study?
This clinical trial studies the following conditions: Hypercholesterolemia.
What interventions are being tested in trial NCT05763875?
The interventions under investigation include: Ezetimibe (DRUG), Inclisiran (DRUG), Matching Placebo for Inclisiran (DRUG), Matching Placebo for Ezetimibe (DRUG).
Who is sponsoring clinical trial NCT05763875?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05763875 being conducted?
This trial has 20 study locations across Alabama, Florida, Illinois, Louisiana, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypercholesterolemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
ACTIVE NOT RECRUITING · Phase 3
-
Effect of a Decision Aid About Statin Use in Patients With Type 2 Diabetes Mellitus
COMPLETED · Phase 3
-
Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia
COMPLETED · Phase 3
-
Actual Use Trial of Atorvastatin Calcium 10 mg
COMPLETED · Phase 3
-
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
COMPLETED · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018) CORALreef AddOn
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.